SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Jesse Owens Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJesse Owens
Date of birth1913-09-12
IdentifiersMRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319
Document date2026-11-01
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment. Concerns: He wants to know quickly and plainly whether the spot on the scan is cancer, and what can be done; He has smoked for 35 years, has failed to stop twice on his own, and worries that stopping now is pointless; No doctor had offered him a lung scan before; he wants the same care anyone else would get, without delay; He wants to keep speaking to young people and to keep walking every morning. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route1979-05-26 to 1979-06-01completedS
Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse1 mg twice daily after foodOral route1979-06-02activeS
Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)Day 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cyclesDay 1 every 21 days for three cyclesIntravenous route1979-06-03 to 1979-07-15completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route1979-05-26 to 1979-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route1979-05-26 to 1979-05-26completedS
Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose4 mg twice daily for three days around each cycleOral route1979-06-02 to 1979-07-16completedS
Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy8 mg every 8 hours as neededOral route1979-06-03 to 1979-07-31completedS
Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery1000 mg every 8 hours as neededOral route1979-08-22 to 1979-09-15completedS

Procedures

ProcedureDatesStatusEvidence
Shared decision-making visit for lung cancer screening with a decision aid (benefits, false positives, overdiagnosis, radiation, and the need for yearly scans and for tobacco treatment); he chose to be screened1979-05-11 to 1979-05-11completedS
Low-dose CT of the chest without contrast for lung cancer screening (first screen): solid, spiculated 2.9 cm nodule in the apicoposterior segment of the left upper lobe; enlarged left hilar lymph node 1.6 cm in short axis; mild centrilobular emphysema in both upper lobes; coronary artery calcification, moderate; Lung-RADS 4X (category 4B with additional features of malignancy)1979-05-11 to 1979-05-11completedS
Chest X-ray, posteroanterior and lateral: the left upper lobe nodule is smaller than on the screening CT; no new opacity, consolidation or ground-glass change; no effusion1979-07-06 to 1979-07-06completedS
Advance care planning conversation, about 25 minutes, with his consent1979-10-21 to 1979-10-21completedS
FDG PET-CT: avid left upper lobe nodule, 2.9 cm (SUVmax 9.8); avid left interlobar (11L) node, 1.6 cm (SUVmax 6.1); no avid mediastinal, supraclavicular or contralateral node; no distant uptake. The infrarenal abdominal aorta measures 2.1 cm1979-05-14 to 1979-05-14completedS
MRI of the brain with contrast: no metastases1979-05-15 to 1979-05-15completedS
Endobronchial ultrasound with systematic needle aspiration of stations 4R, 4L, 7, 10L and 11L under moderate sedation: adenocarcinoma in 11L (TTF-1 positive); 4R, 4L, 7 and 10L negative with adequate lymphocytes; PD-L1 (22C3) tumor proportion score 40 percent; tissue next-generation sequencing (reported in six days, with concordant plasma testing): KRAS G12C mutation, STK11 and KEAP1 wild type; no EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK or HER2 alteration1979-05-19 to 1979-05-19completedS
Thoracic multidisciplinary tumor board (thoracic surgery, medical and radiation oncology, pulmonology, radiology, pathology, nurse navigator): resectable cT1c N1 M0 stage IIB adenocarcinoma, no EGFR or ALK alteration; recommends three cycles of nivolumab with platinum doublet chemotherapy, restaging, then lobectomy1979-05-21 to 1979-05-21completedS
Pulmonary function tests: spirometry and DLCO (FEV1 2.71 L, 86 percent predicted; FEV1/FVC 0.73; DLCO 86 percent predicted). Predicted postoperative values after left upper lobectomy (14 of 19 segments remaining): FEV1 63 percent and DLCO 63 percent1979-05-26 to 1979-05-26completedS
Pulmonary rehabilitation as prehabilitation during chemoimmunotherapy: 16 supervised sessions of aerobic and strength training with breathing exercises, twice weekly1979-06-08 to 1979-08-14completedS
Restaging CT of the chest and upper abdomen with contrast after three cycles: left upper lobe nodule 1.3 cm (from 2.9 cm); left interlobar node 0.8 cm (from 1.6 cm); no new nodule, node, effusion or ground-glass change; no liver or adrenal lesion1979-07-31 to 1979-07-31completedS
Video-assisted thoracoscopic left upper lobectomy with systematic mediastinal (stations 4L, 5, 6, 7, 8, 9) and hilar lymph node dissection; three days in hospital without complications. Pathology: ypT1a N0 (0 of 16 nodes; treatment effect without viable tumor in the 11L node), 0.7 cm residual adenocarcinoma with 6 percent viable tumor (major pathologic response), margins clear (R0)1979-08-19 to 1979-08-22completedS
Pulmonary rehabilitation after lobectomy: a 12-week program, twice weekly, started1979-10-05 to 1979-10-05completedS

Immunizations

DateVaccineStatusEvidence
1979-05-26Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapycompletedS
1979-10-21Influenza vaccine, high-dose, this seasoncompletedS
1979-10-21COVID-19 mRNA vaccine, this season's formulacompletedS
1979-10-21Respiratory syncytial virus vaccine, single dosecompletedS
1979-10-21Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
about 1920Pneumonia at about age 7, during an epidemic in Alabama, from which he nearly died; a sickly, underweight childhood in povertyD (CLM-0002)

Family History

RelativeConditionAge at deathEvidence
brotherDied in childhood during the epidemic in which he had pneumonia; cause not recorded in the cited sourceD (CLM-0002)
sisterDied in childhood during the same epidemic; cause not recorded in the cited sourceD (CLM-0002)

Health Concerns

ConcernStatusEvidence
He wants to know quickly and plainly whether the spot on the scan is cancer, and what can be doneactiveS
He has smoked for 35 years, has failed to stop twice on his own, and worries that stopping now is pointlessactiveS
No doctor had offered him a lung scan before; he wants the same care anyone else would get, without delayactiveS
He wants to keep speaking to young people and to keep walking every morningactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.1 on 1979-07-06; Leukocytes [#/volume] in Blood by Automated count 5.4 on 1979-07-06; Platelets [#/volume] in Blood by Automated count 176 on 1979-07-06; Sodium [Moles/volume] in Serum or Plasma 138 on 1979-08-05; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1979-08-05; Creatinine [Mass/volume] in Serum or Plasma 1 on 1979-09-30; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M 84 on 1979-09-30; Glucose [Mass/volume] in Serum or Plasma 92 on 1979-09-30; Calcium [Mass/volume] in Serum or Plasma 9.3 on 1979-08-05; Albumin [Mass/volume] in Serum or Plasma 4 on 1979-08-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1979-09-30; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1979-09-30; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 90 on 1979-08-05; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 1979-09-30; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1979-10-21; Neutrophils [#/volume] in Blood by Automated count 3.2 on 1979-07-06; Thyrotropin [Units/volume] in Serum or Plasma 4.6 on 1979-09-30; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1979-09-30; Cortisol [Mass/volume] in Serum or Plasma 12.9 on 1979-08-05; FEV1 2.71 on 1979-05-26; FEV1 measured/predicted 86 on 1979-05-26; FEV1/FVC 0.73 on 1979-05-26; Diffusion capacity.carbon monoxide 23.6 on 1979-05-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1979-05-26; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 1979-05-26; Total score [Mini-Cog] 5 on 1979-10-21; Total score [AUDIT-C] 2 on 1979-10-21 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineresolvedconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.
Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.
After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor)activeconfirmed Z90.2S — Synthetic consequence of the synthetic operation.
Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on vareniclineactiveconfirmed F17.211S — Synthetic modern entry linked to his documented smoking.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-05-11Hemoglobin [Mass/volume] in Blood15.1g/dL13.5-17.5 g/dLNormalS
1979-05-11Leukocytes [#/volume] in Blood by Automated count8.410*3/uL4-11 10*3/uLNormalS
1979-05-11Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
1979-05-11Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1979-05-11Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1979-05-11Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
1979-05-11Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-05-11Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1979-05-11Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1979-05-11Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
1979-05-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
1979-05-11Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-48 U/LNormalS
1979-05-11Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma84U/L40-129 U/LNormalS
1979-05-11Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1979-05-11Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1979-05-26Hemoglobin [Mass/volume] in Blood14.9g/dL13.5-17.5 g/dLNormalS
1979-05-26Leukocytes [#/volume] in Blood by Automated count8.110*3/uL4-11 10*3/uLNormalS
1979-05-26Neutrophils [#/volume] in Blood by Automated count5.210*3/uL1.5-7.7 10*3/uLNormalS
1979-05-26Platelets [#/volume] in Blood by Automated count25810*3/uL150-400 10*3/uLNormalS
1979-05-26Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
1979-05-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-05-26Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
1979-05-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L7-55 U/LNormalS
1979-05-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
1979-05-26Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1979-05-26Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
1979-05-26Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1979-05-26Cortisol [Mass/volume] in Serum or Plasma13.8ug/dLMorning (8 a.m.) reference intervalNormalS
1979-05-26FEV12.71LLower limit of normal for his age and height (GLI 1965)NormalS
1979-05-26FEV1 measured/predicted86%>=80%NormalS
1979-05-26FEV1/FVC0.73{ratio}Below 0.70 after bronchodilator indicates airflow obstructionNormalS
1979-05-26Diffusion capacity.carbon monoxide23.6mL/min/mm[Hg]Lower limit of normal for his age and height; predicted 27.4NormalS
1979-05-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1979-05-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
1979-06-24Hemoglobin [Mass/volume] in Blood13.6g/dL13.5-17.5 g/dLNormalS
1979-06-24Leukocytes [#/volume] in Blood by Automated count6.910*3/uL4-11 10*3/uLNormalS
1979-06-24Neutrophils [#/volume] in Blood by Automated count4.110*3/uL1.5-7.7 10*3/uLNormalS
1979-06-24Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
1979-06-24Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
1979-06-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-06-24Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
1979-06-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
1979-06-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L8-48 U/LNormalS
1979-06-24Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1979-06-24Thyrotropin [Units/volume] in Serum or Plasma2.6m[IU]/L0.4-4 mIU/LNormalS
1979-06-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1979-06-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1979-08-05Hemoglobin [Mass/volume] in Blood12.8g/dL13.5-17.5 g/dLLowS
1979-08-05Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
1979-08-05Neutrophils [#/volume] in Blood by Automated count3.610*3/uL1.5-7.7 10*3/uLNormalS
1979-08-05Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1979-08-05Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1979-08-05Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1979-08-05Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.7-1.3 mg/dLNormalS
1979-08-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M74mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-08-05Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1979-08-05Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1979-08-05Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1979-08-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
1979-08-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-48 U/LNormalS
1979-08-05Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma90U/L40-129 U/LNormalS
1979-08-05Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1979-08-05Thyrotropin [Units/volume] in Serum or Plasma6.8m[IU]/L0.4-4 mIU/LHighS
1979-08-05Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
1979-08-05Cortisol [Mass/volume] in Serum or Plasma12.9ug/dLMorning (8 a.m.) reference intervalNormalS
1979-08-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1979-09-30Hemoglobin [Mass/volume] in Blood13.4g/dL13.5-17.5 g/dLLowS
1979-09-30Leukocytes [#/volume] in Blood by Automated count710*3/uL4-11 10*3/uLNormalS
1979-09-30Neutrophils [#/volume] in Blood by Automated count4.310*3/uL1.5-7.7 10*3/uLNormalS
1979-09-30Platelets [#/volume] in Blood by Automated count24610*3/uL150-400 10*3/uLNormalS
1979-09-30Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
1979-09-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1979-09-30Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1979-09-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1979-09-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
1979-09-30Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1979-09-30Thyrotropin [Units/volume] in Serum or Plasma4.6m[IU]/L0.4-4 mIU/LHighS
1979-09-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1979-09-30Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1979-07-06Hemoglobin [Mass/volume] in Blood13.1g/dL13.5-17.5 g/dLLowS
1979-07-06Leukocytes [#/volume] in Blood by Automated count5.410*3/uL4-11 10*3/uLNormalS
1979-07-06Neutrophils [#/volume] in Blood by Automated count3.210*3/uL1.5-7.7 10*3/uLNormalS
1979-07-06Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS
1979-10-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1979-10-21Total score [Mini-Cog]5{score}S
1979-10-21Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1979-05-11Body height178cmS
1979-05-11Body weight77kgS
1979-05-11Body mass index (BMI) [Ratio]24.3kg/m2S
1979-05-11Systolic blood pressure134mm[Hg]S
1979-05-11Diastolic blood pressure82mm[Hg]S
1979-05-11Heart rate78/minS
1979-05-11Respiratory rate16/minS
1979-05-11Body temperature36.7CelS
1979-05-11Oxygen saturation in Arterial blood by Pulse oximetry95%S
1979-05-26Body height178cmS
1979-05-26Body weight76.6kgS
1979-05-26Body mass index (BMI) [Ratio]24.2kg/m2S
1979-05-26Systolic blood pressure130mm[Hg]S
1979-05-26Diastolic blood pressure80mm[Hg]S
1979-05-26Heart rate80/minS
1979-05-26Respiratory rate16/minS
1979-05-26Body temperature36.6CelS
1979-05-26Oxygen saturation in Arterial blood by Pulse oximetry95%S
1979-06-24Body height178cmS
1979-06-24Body weight75.8kgS
1979-06-24Body mass index (BMI) [Ratio]23.9kg/m2S
1979-06-24Systolic blood pressure126mm[Hg]S
1979-06-24Diastolic blood pressure78mm[Hg]S
1979-06-24Heart rate74/minS
1979-06-24Respiratory rate16/minS
1979-06-24Body temperature36.6CelS
1979-06-24Oxygen saturation in Arterial blood by Pulse oximetry96%S
1979-08-05Body height178cmS
1979-08-05Body weight75.2kgS
1979-08-05Body mass index (BMI) [Ratio]23.7kg/m2S
1979-08-05Systolic blood pressure124mm[Hg]S
1979-08-05Diastolic blood pressure76mm[Hg]S
1979-08-05Heart rate72/minS
1979-08-05Respiratory rate14/minS
1979-08-05Body temperature36.5CelS
1979-08-05Oxygen saturation in Arterial blood by Pulse oximetry97%S
1979-09-30Body height178cmS
1979-09-30Body weight74.6kgS
1979-09-30Body mass index (BMI) [Ratio]23.5kg/m2S
1979-09-30Systolic blood pressure122mm[Hg]S
1979-09-30Diastolic blood pressure76mm[Hg]S
1979-09-30Heart rate76/minS
1979-09-30Respiratory rate16/minS
1979-09-30Body temperature36.6CelS
1979-09-30Oxygen saturation in Arterial blood by Pulse oximetry96%S
1979-07-06Body height178cmS
1979-07-06Body weight75.6kgS
1979-07-06Body mass index (BMI) [Ratio]23.9kg/m2S
1979-07-06Systolic blood pressure128mm[Hg]S
1979-07-06Diastolic blood pressure78mm[Hg]S
1979-07-06Heart rate84/minS
1979-07-06Respiratory rate16/minS
1979-07-06Body temperature37.6CelS
1979-07-06Oxygen saturation in Arterial blood by Pulse oximetry96%S
1979-10-21Body height178cmS
1979-10-21Body weight75kgS
1979-10-21Body mass index (BMI) [Ratio]23.7kg/m2S
1979-10-21Systolic blood pressure124mm[Hg]S
1979-10-21Diastolic blood pressure76mm[Hg]S
1979-10-21Heart rate70/minS
1979-10-21Respiratory rate16/minS
1979-10-21Body temperature36.6CelS
1979-10-21Oxygen saturation in Arterial blood by Pulse oximetry96%S

Encounters

DatePurposeStatusProvenance
1979-05-11New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatmentfinishedS
1979-05-26Diagnosis of left upper lobe adenocarcinoma, stage IIB: thoracic oncology consultation, tumor board plan for chemoimmunotherapy before surgery, and start of vareniclinefinishedS
1979-06-24Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitationfinishedS
1979-08-05After three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparationfinishedS
1979-09-30Six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitationfinishedS
1979-07-06Same-day sick visit for a cold during chemoimmunotherapyfinishedS
1979-10-21Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Referral to thoracic oncology: consultation within two weeks to review the screening CT, PET-CT and EBUS results with him and plan treatmentcompletedGL-NCCN-NSCLC-2026, GL-CMID-2026S
Work-up of the Lung-RADS 4X nodule without delay: FDG PET-CT and brain MRI with contrast this week, then endobronchial ultrasound with systematic sampling of mediastinal and hilar nodes (at least stations 4R, 4L and 7, and any PET-avid node), with enough tissue for PD-L1 and comprehensive next-generation sequencing (EGFR, ALK, ROS1, BRAF, KRAS, MET exon 14, RET, NTRK, HER2) and plasma testing in parallel; nurse navigator to track each datecompletedGL-USPSTF-LUNG-2021, GL-ACCP-SCREEN-2021, GL-ACR-LUNGRADS-2022, GL-NCCN-NSCLC-2026, GL-ACCP-STAGING-2013S
Tobacco treatment at every visit: brief advice, varenicline offered with a quit date, the Arizona quitline and counseling; stopping smoking improves outcomes even after a lung cancer diagnosiscompletedGL-USPSTF-TOB-2021, GL-CMID-2026S
Equity safeguards: a nurse navigator, written results and next steps at each visit, transport and cost help offered, and time from scan to treatment tracked against the goalcompletedGL-ALDRICH-2019, GL-BACH-1999S
Distress and depression screening at each visit, plain information he can share, and advance care planning when he is readycompletedGL-CMID-2026S
Chemoimmunotherapy before surgery: nivolumab 360 mg with carboplatin (AUC 5) and pemetrexed 500 mg/m2 every three weeks for three cycles, with folic acid, vitamin B12 and dexamethasone premedication, hepatitis B, hepatitis C and HIV tests first, and restaging CT before surgerycompletedGL-NCCN-NSCLC-2026, GL-CHECKMATE816-2022S
Immune-related adverse event monitoring: TSH, free T4, liver tests, creatinine, glucose and blood count before each cycle, morning cortisol at baseline and before surgery, and a written list of warning symptoms with a 24-hour oncology linecompletedGL-ASCO-IRAE-2021, GL-CMID-2026S
Physiologic evaluation for lobectomy (spirometry and DLCO with predicted postoperative values) and prehabilitation: a pulmonary rehabilitation program during chemotherapycompletedGL-ACCP-PHYS-2013, GL-CMID-2026S
Thoracoscopic left upper lobectomy with systematic mediastinal and hilar lymph node dissection after restaging shows response and no new diseasecompletedGL-NCCN-NSCLC-2026, GL-ACCP-EARLY-2013S
After surgery: no further systemic therapy after a major pathologic response, by shared decision; history, examination and chest CT every six months for two to three years, then yearly low-dose CT; pulmonary rehabilitation after surgery; the KRAS G12C result kept on file for any recurrencecompletedGL-NCCN-NSCLC-2026, GL-ASCO-SURV-2020, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT1979-05-26completedPET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scanS
Stop smoking completely before treatment starts and stay stopped1979-09-30completedNo cigarettes since day 1 of cycle 1, about four months; varenicline continued to complete 24 weeksS
Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher1979-08-05completedThree cycles on schedule; only a grade 1 rise in TSH, monitored without treatmentS
Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle1979-09-30completedThoracoscopic left upper lobectomy five weeks after cycle 3; R0; major pathologic responseS
Back to walking 3 km most mornings by three months after surgery1979-09-30completedWalking 2 km a day six weeks after surgery and starting pulmonary rehabilitationS

Functional Status

Mental Status